Reduction of the total IgE level by omalizumab in children and adolescents

Journal of Asthma

Volumn 45, Issue 3, 2008, Pages 233-236

  Steiss, J O ^a,c   Strohner, P ^b   Zimmer, K P ^a   Lindemann, H ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b BioTeZ Berlin Buch GmbH   (Germany)

^c JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

Allergic bronchial asthma; IgE assay; Omalizumab; Total immunoglobulin E

Indexed keywords

IMMUNOGLOBULIN E; OMALIZUMAB;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; AGE DISTRIBUTION; ALLERGIC ASTHMA; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DISEASE EXACERBATION; DRUG TOLERABILITY; ENZYME IMMUNOASSAY; FEMALE; FOOD ALLERGY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; INSECT STING; MALE; NEURODERMATITIS; PEANUT ALLERGY; QUALITY OF LIFE; RHINOCONJUNCTIVITIS; SCHOOL CHILD; SEVERE PERSISTENT ASTHMA; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CHILD; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE;

EID: 42249095033     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1080/02770900701883782     Document Type: Article

References (19)

1. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa GD. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2004, 60:302-308.
2. Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Thirwell J, Cioppa GD: Omalizumab 011 International Study Group:Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004, 34:632-638.
3. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006; Apr; (2); CD003559
4. Owen CE. Immunoglobulin E:Role in asthma and allergic disease:Lessons from the clinic. Pharmacol Therapeutics 2007; 113:121-133.
5. Hochhaus G, Brookman L, Fox H, Johanson C, Matthews J, Ren S, Deniz Y. Pharmacodynamics of Omalizumab:implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003, 19:491-498.
6. Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006; 54:68-72.
7. van der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007; 62:276-277.
8. Buhl R, Berdel D, Criee CP, Gillissen A, Kardos P, Kroegel C, Leupold W, Lindemann H, Magnussen H, Nowak D, Pfeiffer-Kascha D, Rabe K, Rolke M, Schultze-Werninghaus G, Sitter H, Ukena D, Vogelmeier C, Welte T, Wettengel R, Worth H. Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma. Pneumologie 2006; 60:139-183.
9. Petersen AB, Gudmann P, Milvang-Gronager P, Morkeberg R, Bogestrand S, Linneberg A, Johansen N. Performance evaluation of a specific IgE assay developed for the ADVIA Centaur® immunoassay system. Clinical Biochemistry 2004; 37:882-892.
10. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-190.
11. Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirwell J, Gupta N, Della Cioppa G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-261.
12. Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalisations in patients with allergic asthma. J Allergy Clin Immunol 2003; 111:87-90.
13. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis (SOLAR). Allergy 2004, 59:709-717.
14. Hamilton RG, Marcotte GV, Saini SS:Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving Omalizumab (Xolair) therapy. J Immunol Methods 2005, 303:81-91.
15. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment, INNOVATE). Allergy 2005; 60:309-316.
16. Ruffin CG, Busch BE. Omalizumab:a recombinant humanized anti-IgE antibody for allergic asthma. Am J Health Syst Pharm 2004; 61:1449-1455.
17. Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, Dockhorn RJ, Reimann J, SuJQ, Fick RB, Adelman DC. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100:110-121.
18. Bousquet J, Rabe K, Humbert M, Chung KF, berger W, Fox H, Ayre G, Chen H, Thomas K, Blogg M, Holgate S. Predicting and evaluating response omalizumab on patients with severe allergic asthma. Respir Med 2007; 101:1483-1492. Epub 2007 Mar 6.
19. Hanf G, Brachmann I, Kleine-Tebbe J, Seybold J, Kunkel G, Suttorp N, Noga O. Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma. Allergy 2007; 61:1141-1144.